Pillars of growth

Enoxaparin BIOSIMILAR

Enoxaparin Biosimilar represents an excellent growth opportunity for ROVI considering the significant medical need. Enoxaparin Biosimilar was launched in the UK in March 2018 and is marketed under the brand AROVI®.

Find out +

Especialidades farmacéuticas

Enoxaparin BIOSIMILAR

Enoxaparin Biosimilar represents an excellent growth opportunity for ROVI considering the significant medical need. Enoxaparin Biosimilar was launched in the UK in March 2018 and is marketed under the brand AROVI®.

Find out +

Especialidades farmacéuticas

Research, Development and Innovation
(R&D and I)

R&D and I as an engine for future growth.
Find out +

Contract Manufacturing

High production capacity with four manufacturing plants for pre-filled syringes, oral solids and active principles.

Find out +

Rovi en cifras

Rovi in figures

276

millions euros2017 Operating Revenue

56
countries

Bemiparin international presencewith 22 international partners

4
plants

for the production of own products and third party products in Spain

28,3 Mn€

Invested in R&D in 2017committed to innovation

6 countries

Direct presencethrough subsidiaries to market Enoxaparin

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to shareholders and investors